PL441319A1 - Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro - Google Patents
Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitroInfo
- Publication number
- PL441319A1 PL441319A1 PL441319A PL44131922A PL441319A1 PL 441319 A1 PL441319 A1 PL 441319A1 PL 441319 A PL441319 A PL 441319A PL 44131922 A PL44131922 A PL 44131922A PL 441319 A1 PL441319 A1 PL 441319A1
- Authority
- PL
- Poland
- Prior art keywords
- colorectal cancer
- timp
- protein biomarkers
- vitro method
- diagnosing colorectal
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title abstract 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract 4
- 239000000090 biomarker Substances 0.000 title abstract 3
- 238000000338 in vitro Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- -1 GRO-a Proteins 0.000 abstract 2
- 108091058560 IL8 Proteins 0.000 abstract 2
- 102000004890 Interleukin-8 Human genes 0.000 abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 abstract 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 abstract 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 abstract 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Przedmiotem zgłoszenia jest zestaw biomarkerów białkowych do diagnozowania in vitro wczesnego stadium raka jelita grubego albo raka jelita grubego zawierający TIMP-1, TIMP-2, IL8, GRO-a, HGF i Ang-1. Kolejnym przedmiotem zgłoszenia jest sposób diagnozowania in vitro wczesnego stadium raka jelita grubego albo raka jelita grubego obejmujący ocenę poziomu ekspresji w pęcherzykach pozakomórkowych co najmniej dwóch biomarkerów z grupy obejmującej TIMP-1, TIMP-2, IL8, GRO-a, HGF i Ang-1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL441319A PL441319A1 (pl) | 2022-05-31 | 2022-05-31 | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro |
EP23461600.1A EP4286854A3 (en) | 2022-05-31 | 2023-05-31 | Set of protein biomarkers and method for diagnosing colorectal cancer in vitro |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL441319A PL441319A1 (pl) | 2022-05-31 | 2022-05-31 | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro |
Publications (1)
Publication Number | Publication Date |
---|---|
PL441319A1 true PL441319A1 (pl) | 2023-12-04 |
Family
ID=87514370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL441319A PL441319A1 (pl) | 2022-05-31 | 2022-05-31 | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4286854A3 (pl) |
PL (1) | PL441319A1 (pl) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127219A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
WO2012006681A1 (en) * | 2010-07-14 | 2012-01-19 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic for colorectal cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2827894A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
CA2838728A1 (en) * | 2011-06-07 | 2012-12-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for cancer |
EP2841947B1 (en) | 2012-04-26 | 2019-10-09 | Stichting VUmc | Biomarkers |
CN110799841B (zh) | 2017-06-30 | 2024-02-02 | 国立研究开发法人医药基盘·健康·营养研究所 | 用于检测大肠癌的生物标志物 |
US20220214345A1 (en) | 2019-05-08 | 2022-07-07 | Deutsches Krebsforschungszentrum Sitftung des öffentlichen Rechts | Colorectal cancer screening examination and early detection method |
-
2022
- 2022-05-31 PL PL441319A patent/PL441319A1/pl unknown
-
2023
- 2023-05-31 EP EP23461600.1A patent/EP4286854A3/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127219A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
WO2012006681A1 (en) * | 2010-07-14 | 2012-01-19 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic for colorectal cancer |
Non-Patent Citations (1)
Title |
---|
HUANG, CH. IIN.: "Oncotarget, 2017, vol. 8 (No. 14), 23459-23469", "HEPATOCYTE GROWTH FACTOR IS A PROGNOSTIC MARKER IN PATIENTS WITH COLORECTAL CANCER: A META-ANALYSIS" * |
Also Published As
Publication number | Publication date |
---|---|
EP4286854A2 (en) | 2023-12-06 |
EP4286854A3 (en) | 2024-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer | |
Jatzko et al. | Long-term results of radical surgery for rectal cancer: multivariate analysis of prognostic factors influencing survival and local recurrence | |
Cvetkovic et al. | Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer | |
Barber et al. | Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer | |
Huang et al. | EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function | |
Davila et al. | Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction | |
Nagai et al. | Metachronous intraductal papillary mucinous neoplasms disseminate via the pancreatic duct following resection | |
Sangoi et al. | Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact | |
Kashibuchi et al. | The prognostic value of E-cadherin, α-, β-, and γ-catenin in urothelial cancer of the upper urinary tract | |
Hong et al. | The role of GPX1 in the pathogenesis of female pelvic organ prolapse | |
Tabata et al. | Nestin is an independent predictor of cancer-specific survival after radical cystectomy in patients with urothelial carcinoma of the bladder | |
KR102265529B1 (ko) | 복합 유전 정보 네트워크 분석에 기반한 질병 위험도 진단 방법 | |
PL441319A1 (pl) | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro | |
US11899019B2 (en) | Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy | |
Stallone et al. | Semaphorin 3F expression is reduced in pregnancy complicated by preeclampsia. An observational clinical study | |
Canguçu et al. | The prognostic influence of tumour budding in Western patients with stage II colorectal cancer | |
Cienfuegos et al. | Screening-detected colorectal cancers show better long-term survival compared with stage-matched symptomatic cancers | |
Metcalfe et al. | Impact of high-risk features and effect of neoadjuvant chemotherapy in urothelial cancer patients with invasion into the lamina propria on transurethral resection in the absence of deep muscle invasion | |
Kuratomi et al. | Diffuse expression of laminin γ2 chain in disseminating and infiltrating cancer cells indicates a highly malignant state in advanced tongue cancer | |
Kim et al. | The benefit of liver transplant beyond Milan criteria: an analysis using the National Cancer Database | |
He et al. | Use of mesothelin as a tumor-associated antigen in cervical squamous cell carcinoma | |
Šundov et al. | Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke’s B colon cancer | |
CN105209641A (zh) | 用于前列腺癌和其他疾病的诊断和预后生物标记物 | |
Jacob et al. | S299 How Often Do We Provide Recommendations to Patients With Colorectal Cancer or Advanced Colonic Adenomas on When Their First-Degree Relatives Should Begin Colorectal Cancer Screening? | |
Alvarez et al. | TGF-beta RECEPTOR INHIBITION INCREASES PD-L1 EXPRESSION IN PANCREATIC CANCER |